TLR3 and influenza: TLR3 agonists have been used previously as safe adjuvants for intranasal immunization of human volunteers with trivalent influenza vaccine or as monotherapy post-exposure prophylaxis given up to 48 h post challenge with influenza or rhinovirus15,16.